Mirvetuximab Soravtansine-gynx

Phase 2Antibody–drug conjugate

UUniversity of Colorado, Denver

Mirvetuximab Soravtansine-gynx is one of 2 small molecule programs targeting Ovary Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovary CancerRecruiting

Ovary CancerPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Ovary Cancer

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Phase 2

1 2

Mirvetuximab Soravtansine-gynx

UUniversity of Colorado, Denver

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Recruiting

Ovary Cancer

NCT05887609

Clinical

Trials by Indication[1]

Ovary Cancer1 trial

A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine-gynx and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05887609·53 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mirvetuximab Soravtansine-gynx. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mirvetuximab Soravtansine-gynx compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mirvetuximab Soravtansine-gynx. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Denver company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Colorado, Denver

Mirvetuximab Soravtansine-gynx

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Ovary Cancer1 trial

References

Drug Info

Quick Facts

Related News